13 results about "Drug accumulation" patented technology

This invention discloses a nanomedicine and its application in the four-modal synergistic treatment of ER+ breast cancer, encompassing gas therapy, photothermal therapy, photodynamic therapy, and combined therapy, relating to the fields of biotechnology and new medicine. This nanomedicine uses an amphiphilic polymer as a carrier and organic compounds and photosensitizers as drug loading agents. Through the synergistic effects of four modes—photothermal, photodynamic, gas therapy, and combined therapy—it effectively inhibits the growth and metastasis of breast cancer cells. The amphiphilic polymer, based on PHHM-ADT, is modified with hydrogen sulfide gas as a donor, and its amphiphilicity allows for spontaneous assembly into nanoscale hollow, regular spheres. Utilizing the high permeability and retention effect (EPR effect) at the tumor site, it achieves efficient drug accumulation in tumor tissue. The prodrug PSF couples fulvestrant and pabuxiparin via disulfide bonds, and the photosensitizer IR808 integrates photothermal and photodynamic therapy. The synergistic effect of multiple mechanisms of action enhances the therapeutic effect.

This invention relates to the field of biomedical technology, specifically to an antifungal nanoparticle, a combination drug, and its application. The antifungal nanoparticle is prepared by covalently linking the aptamer AU1 to drug-loaded silk fibroin nanoparticles via amide bonds. The mass ratio of the drug-loaded silk fibroin nanoparticles to the aptamer AU1 is 20:0.5~2.0. The antifungal nanoparticles of this invention are prepared by a desolvation method using voriconazole-loaded silk fibroin nanoparticles, and the targeting aptamer AU1 is attached to their surface using a carbodiimide chemical cross-linking method. This allows for specific recognition of Candida albicans, increasing drug accumulation at the infection site. Further combination with methylene blue-mediated photodynamic therapy can disrupt biofilm structures, enhance nanoparticle penetration, achieve synergistic bactericidal activity, and reduce systemic toxicity, providing a novel, highly effective, and low-toxicity treatment strategy for fungal biofilm infections.

The invention relates to a grinding device for pharmacy. The grinding device comprises a supporting base, a tamping rod frame is connected to the supporting base, a grinding tank is arranged on the lower portion of the tamping rod frame, an electric secondary telescopic rod is connected to the upper portion of the tamping rod frame, a grinding block is connected to the telescopic end of the electric secondary telescopic rod, and a driving piece is connected between the tamping rod frame and the grinding tank. The technical scheme of the invention has the beneficial technical effects that the electric secondary telescopic rod is adopted to drive the grinding block to realize lifting, extruding and grinding, so that each medicine raw material can be in uniform contact with the extruding and grinding surface of the grinding block, the problem of non-uniform grinding caused by local accumulation and corner residues of medicines is effectively avoided, and the granularity consistency of final ground products is ensured. The synergistic grinding mode is especially suitable for scenes with high requirements on the fineness of medicine powder in pharmaceutical research and preparation production, high-quality raw materials can be provided for subsequent medicine dissolution, mixing and preparation forming, and the dissolution rate and the medicine effect stability of the medicine are indirectly guaranteed.

The present invention discloses the use of a short-term embolic agent in reducing drug accumulation in the liver, hepatic clearance and / or liver toxicity. The present invention provides the use of a short-term embolic agent in the manufacture of a medical composition for: (a) temporarily embolizing blood vessels supplying the liver; and (b) reducing the accumulation of a drug subsequently or concurrently administered intravenously in the liver. The strategy aims to minimize the exposure of a drug (such as LNP) to the liver by temporarily blocking the blood supply to the liver via the portal vein and / or arteries. The present invention significantly reduces the non-specific accumulation of a drug in the liver by temporarily blocking the portal vein, arterial and / or their branch blood flow, thereby greatly reducing the opportunity for the drug to enter the liver from a hemodynamic root.

This invention discloses a nanoemulsion gel containing Sichuan pepper volatile oil, its preparation method, and its application. The Sichuan pepper volatile oil nanoemulsion gel of this invention comprises a core layer and an encapsulation layer. The core layer is a nanoemulsion loaded with Sichuan pepper volatile oil, and the encapsulation layer is a carboxymethyl chitosan-sodium alginate composite hydrogel. The composite hydrogel forms a three-dimensional network structure through calcium ion cross-linking, encapsulating the Sichuan pepper volatile oil-loaded nanoemulsion within it. This invention prepares Sichuan pepper volatile oil into a nanoemulsion, significantly improving its water solubility and chemical stability, and reducing degradation in the gastrointestinal tract after oral administration. Further encapsulation with the carboxymethyl chitosan-sodium alginate composite hydrogel utilizes the pH sensitivity and colonic enzyme responsiveness of the composite hydrogel to reduce drug release in the stomach and small intestine, allowing the drug to degrade and release upon reaching the colon, thus increasing drug accumulation at sites of colonic inflammation. This solves the problems of poor targeting and low bioavailability of Sichuan pepper volatile oil.

This invention discloses an injectable hydrogel loaded with 4-octyl itaconic acid, its preparation method, and its applications, belonging to the field of biomedical materials technology. The injectable hydrogel is formed by enzymatic cross-linking of a hyaluronic acid-tyramine complex to create a three-dimensional network, with 4-octyl itaconic acid encapsulated within this network structure. This invention allows for precise implantation of the hydrogel into the intervertebral disc lesion via minimally invasive injection, achieving local high-concentration drug accumulation. The three-dimensional network of the hydrogel serves as a drug reservoir, enabling continuous and controllable release of 4-OI, prolonging the drug's duration of action and achieving long-term therapeutic effects. Simultaneously, the loaded 4-OI specifically activates the Nrf2 / GPX4 antioxidant pathway in nucleus pulposus cells, mechanistically antagonizing ferroptosis and matrix degradation, thus achieving a dual function of mechanical support and biological therapy. It exhibits good biocompatibility and solves the problems of difficult targeted drug delivery, short-lived efficacy, and lack of disease-modifying effects in existing treatments for intervertebral disc degeneration.

This invention relates to a brain-targeting nanomedicine formulation for glioblastoma and its preparation method, belonging to the field of pharmaceutical technology. The formulation comprises an active pharmaceutical ingredient, an amphiphilic block copolymer carrier, a covalently bonded brain-targeting ligand, and a stabilizer. The preparation method includes: chemically coupling the targeting ligand to the carrier material; self-assembling the drug, modified carrier, and stabilizer into nanoparticles using a nanoprecipitation method; and obtaining the final product through membrane extrusion granulation, purification, and lyophilization. The resulting nanoparticles have uniform particle size, high drug loading, and good stability, and can simultaneously achieve efficient crossing of the blood-brain barrier and specific targeting of glioma cells. In vitro and in vivo experiments show that this formulation can significantly improve drug accumulation at brain tumor sites, inhibit tumor growth, and prolong the survival of model animals. Furthermore, the preparation process is controllable and easily scaled up.

This invention belongs to the field of biomedical technology and discloses a targeted delivery biomimetic nanomedicine and its preparation process. The system includes a polylactic acid-glycolic acid copolymer drug-carrying core, a biomimetic cell membrane coating layer, and a pH-responsive polyethylene glycol-arginine block copolymer embedded therein. The latter is anchored to the outer leaflet by a hexadecyl group, maintaining a weakly negative surface charge at physiological pH to evade immune clearance. In the weakly acidic tumor microenvironment, it triggers arginine guanidine matrix protonation, converting the surface potential to a positive charge and enhancing electrostatic adsorption with tumor cells. The core of this invention lies in constructing a dynamic charge interface with spatiotemporal resolution. This interface achieves sequential activation of immune escape and cell adsorption functions at the system level, rather than a simple superposition. This technical approach not only improves the drug accumulation efficiency at the tumor site but also provides a universal platform for other nanomedical applications requiring microenvironment-responsive surface regulation.

This invention belongs to the field of biomedicine and pharmaceutical technology, and discloses a liposome delivery system for thymus-targeted imaging and / or treatment, its preparation method, and applications. The delivery system uses liposomes as carriers and modifies the carriers with terminal carboxyl-modified polyethylene glycol-phospholipid derivatives (DSPE-PEG-COOH) to form functionalized liposome structures. It can efficiently encapsulate iodine contrast agents (e.g., iodixanol) and covalently couple CD205 antibodies to the liposome surface, thereby achieving active targeting of thymic epithelial cells. This system can enhance the specificity and stability of thymus CT imaging. Furthermore, this delivery platform can also be used to load various therapeutic drugs (such as hydroxyflutamide), achieving local drug accumulation in the thymus region, enhancing the intervention effect while effectively reducing systemic toxicity.

This invention relates to the fields of biomedical engineering and nanomedicine delivery technology, specifically disclosing a homologous membrane nano-targeted drug delivery system for treating acute kidney injury with sepsis. The system includes: preparation of solid silicon spheres; mesoporization and etching; drug loading; preparation of homologous cell membranes; encapsulation and fusion; characterization and quality control. This invention utilizes KTP-modified RBCM vesicles to provide homologous surface proteins / receptors, achieving highly selective recognition and endocytosis of renal tubular cells, significantly improving drug accumulation and bioavailability in diseased kidney tissue, thereby enhancing therapeutic efficacy and reducing systemic exposure. The hollow, mesoporous structure provides high drug loading capacity and controllable release sites. The outer homologous membrane inhibits early leakage under physiological conditions and promotes drug release in inflammatory, acidic microenvironments, or intracellular environments, combining the advantages of sustained release and targeted activation.

This application discloses a bone implant prosthesis, relating to the field of orthopedic implant technology, aiming to solve the problems of uncontrollable drug release, poor targeting, and safety hazards. The prosthesis includes a bone implant matrix and magnetic particles. The magnetic particles are doped into a designated area of ​​the matrix at a low mass percentage of 0.5%-5%, forming a chain-like structure within this area to generate a magnetic field gradient for capturing magnetized drugs, while ensuring the overall magnetic field strength of the prosthesis does not exceed 5 mT. This structure can generate a highly efficient local magnetic field gradient under extremely low overall magnetic field conditions, thereby accurately capturing intravenously injected magnetized drugs and achieving efficient drug accumulation in the lesion area. This invention has the advantages of precise targeting, high safety, compatibility with MRI examination, and flexible and controllable drug delivery protocols.

This invention belongs to the field of biomedical technology and discloses a Schisandra chinensis exosome-like vesicle-mediated targeted delivery formulation of anisodamine and its application in preventing and treating alcohol-induced liver injury. This invention provides a drug delivery system that improves the water solubility and dispersibility of drugs (such as anisodamine) through carrier-free self-assembled nanoparticle formulations. Simultaneously, it utilizes plant-derived vesicles (such as Schisandra chinensis) for encapsulation, leveraging the excellent biocompatibility, targeting, and penetration of exosome-like vesicles to enhance drug accumulation and bioavailability in liver tissue. This drug delivery system not only promises to solve key challenges in the clinical application of drugs such as poor water solubility and low bioavailability, but also provides a new technical approach for the efficient delivery of natural active ingredients, holding significant theoretical and practical importance for promoting the development of hangover relief health products and liver injury treatment drugs.

The application relates to the technical field of chemical medicines, in particular to a kind of dianilopyrimidine macrocycle containing crown ether fragment and its preparation method and application.A series of dianilopyrimidine macrocycle containing crown ether fragment is synthesized in the application, and the problem of poor clinical effect of drug in current brain glioma treatment is overcome.The series of compounds have good inhibitory activity on brain glioma, and are suitable for treating brain glioma and related drug research and development.Moreover, the drug is widely distributed in vivo and is rapidly cleared, so that the possibility of drug accumulation poisoning is avoided;oral bioavailability is moderate (F=18.7%);these findings highlight the advantages and challenges of the pharmacokinetic characteristics of compound 13, and lay a foundation for further optimizing and improving the in-vivo stability and bioavailability strategy.